A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants.
In: Clinical Trials Week, 2024-04-15, S. 31-31
serialPeriodical
Zugriff:
This document provides information about a clinical trial conducted by BeiGene. The trial, NCT06342713, aims to assess the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic profile of a drug called BGB-45035 in healthy participants. The trial consists of four parts and is estimated to be completed by April 30, 2025. The trial is open to both male and female participants between the ages of 18 and 55 years. The responsible party for the trial is BeiGene. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2024-04-15, S. 31-31 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|